LNCaP nuclear extract (Clone FGC)
Active Motif's LNCaP nuclear extract (Clone FGC) was prepared from cell cultures of the human prostate adenocarcinoma LNCaP-FGC cell line. The LNCaP-FGC cell line is a subclone of the fibroblast-like LNCaP parental cell line that was originally derived from a supraclavicular lymph node metastatic lesion of a 50 year old Caucasian male patient with metastatic prostate carcinoma. Prostate cancer is the second most common neoplasia in men. Because it is a hormone-responsive cancer, its treatment at initial stages of development typically involves anti-androgen adjuvant therapy. The LNCaP-FGC subclone retains all the properties of the parental LNCaP cell line, including its malignant characteristics, such as the expression of high levels of acid phosphatase, androgen receptors and Prostate Specific Antigen (PSA), and hormone sensitivity. This cell line is most commonly used in research as a model for human prostate cancer.